Recombinant Bovine Growth Hormone vs Partially Hydrogenated Oils: which is worse?

What is Recombinant Bovine Growth Hormone?

Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).

What is Partially Hydrogenated Oils?

Partially hydrogenated oils (PHOs) are vegetable oils that have been treated with hydrogen gas in the presence of a catalyst to make them semi-solid at room temperature. This process creates artificial trans fatty acids (trans fats) as a byproduct. They were developed in the early 20th century as a cheaper, longer-lasting alternative to lard and butter.

Documented risks

Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.

Partially Hydrogenated Oils: Artificial trans fats (from PHOs) have the most well-established cardiovascular harm of any food ingredient ever banned. Multiple large meta-analyses have confirmed that trans fat consumption increases LDL ('bad') cholesterol, decreases HDL ('good') cholesterol, increases inflammatory markers, and significantly raises cardiovascular disease risk. The Harvard Nurses' Health Study and other landmark prospective studies in the 1990s identified trans fat as uniquely harmful — worse than saturated fat in its cardiovascular effects. A 2006 NEJM meta-analysis by Mozaffarian et al. estimated that eliminating artificial trans fats from the US diet could prevent 72,000 to 228,000 heart attacks per year and 30,000 to 100,000 coronary heart disease deaths annually. The WHO estimates that industrially produced trans fats cause over 500,000 cardiovascular deaths per year globally. The FDA revoked PHOs' GRAS status in 2015 based on this evidence, with compliance by 2018. Denmark banned artificial trans fats in 2003, the first country to do so, and observed a dramatic reduction in cardiovascular mortality in subsequent years.